top of page
  • Completed

The INSURE Study (INSIGHT MM, UVEA-IXA, REMIX): A Pooled Analysis of RRMM treated with IRd

Updated: May 24, 2022

The INSURE Study

insure - ixazomib-ird

2701 The INSURE Study (INSIGHT MM, UVEA-IXA, REMIX): A Pooled Analysis of Relapsed/Refractory Multiple Myeloma (RRMM) Patients (pts) Treated with Ixazomib-Lenalidomide-Dexamethasone (IRd) in Routine Clinical Practice Program: Oral and Poster Abstracts Session: 652. Multiple Myeloma and Plasma cell Dyscrasias: Clinical and Epidemiological: Poster II Hematology Disease Topics & Pathways: Adults, Clinical Research, Health Outcomes Research, Plasma Cell Disorders, Elderly, Diseases, Real World Evidence, Registries, Lymphoid Malignancies, Study Population Sunday, December 12, 2021, 6:00 PM-8:00 PM Conclusions: The findings from this analysis of a large, global, pooled dataset of 566 pts show that the effectiveness of IRd in routine clinical practice is consistent with the efficacy of IRd observed in TOURMALINE-MM1 (median PFS 20.8 vs 20.6 months), with no new safety concerns. Our results suggest a benefit of treatment with IRd in earlier vs later lines, consistent with reports from previous, smaller real-world studies of IRd in RRMM pts. In addition, this analysis provides important insights on the effectiveness of IRd in frail pts, helping to increase the understanding of the achievable outcomes in this subpopulation. Learn more: https://ash.confex.com/ash/2021/webprogram/Paper150150.html

 

COMY 22 - Session 15: Abstract communications

INSURE: A GLOBAL POOLED ANALYSIS (INSIGHT MM, UVEA-IXA, AND REMIX) OF PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) TREATED WITH IXAZOMIB-LENALIDOMIDE, DEXAMETHASONE (IRD) IN ROUTINE CLINICAL PRACTICE


Comentários


Posts Archive
bottom of page